Kosan's leukemia compound granted orphan drug status.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      UNITED States
    • Subject Terms:
      KOSAN Biosciences Inc.; UNITED States. Food & Drug Administration
    • Abstract:
      Reports that Kosan Biosciences Inc.'s anticancer compound, 17-allylamino-17-demethoxygeldanamycin (17-AAG), has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of chronic myelogenous leukemia. Description of 17-AAG; Ability of 17-AAG to inhibit heat shock protein 90-client protein complexes, leading to the degradation of the client proteins; Institutions involved in the clinical trials.